• About us
• Contact

Advertisement

Organisation › Details

Expedeon (Group)

Expedeon is an enabler of exciting advances in medical science and patient care. The Company’s core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon’s technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers’ development and commercialisation objectives. Expedeon’s products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXNN; ISIN: DE000A2YN801). *

 

	Start	2008-01-31 renamed
	End	2020-01-01 renamed
	Group	2invest (Group)
	Today	2invest (Group)
	Predecessor	Novexin Ltd.
	Successor	2invest (Group)
	Industry	proteomic technology
	Industry 2	NVoy technology
	Region	Harston, Cambridgeshire
	Country	United Kingdom (GB)
	City	Heidelberg
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Expedeon AG. (11/11/19). "Press Release: Expedeon AG Signs EUR 120 Million Deal with Abcam for the Sale of Its immunology and Proteomics Business". Heidelberg & Cambridge.
		Record changed: 2023-07-10

Advertisement

More documents for 2invest (Group)

• [1] 4basebio AG. (7/28/20). "Press Release: 4basebio Informs about Takeover Bid by Sparta AG". Heidelberg & Cambridge....
• [2] Expedeon AG. (11/11/19). "Press Release: Expedeon AG Signs EUR 120 Million Deal with Abcam for the Sale of Its immunology and Proteomics Business". Heidelberg & Cambridge....
• [3] Expedeon AG. (8/6/19). "Press Release: Expedeon AG Signs Commercial Agreement with Sona Nanotech". Halifax, Heidelberg & Cambridge....
• [4] Sygnis AG. (5/8/18). "Press Release: Sygnis Completes Acquisition of TGR Biosciences". Heidelberg & Cambridge....
• [5] Sygnis AG. (10/24/17). "Press Release: Sygnis AG Announces the Launch of the Universal Lateral Flow Assay Kit and Associated Patent Filing". Madrid & Heidelberg....
• [6] Sygnis AG. (10/18/17). "Press Release: Sygnis AG Announces Completion of Relocation of Its Innova Biosciences Unit to Allow for Expansion". Madrid & Heidelberg....
• [7] Sygnis AG. (8/3/17). "Press Release: Sygnis AG Reports Financial Results for the Second Quarter and First Six Months of 2017". Madrid & Heidelberg....
• [8] Sygnis AG. (6/6/17). "Press Release: Sygnis AG Announces Management and Supervisory Board Changes. Dr. Heikki Lanckriet Sole CEO". Madrid & Heidelberg....
• [9] Sygnis AG. (5/8/17). "Press Release: Sygnis AG Plans to Acquire Profitable Innova Biosciences Ltd. for EUR 8 Million in Cash and up to 3.5 Million Shares [Not for USA, Canada, Japan and Australia]". Madrid & Heidelberg....
• [10] Sygnis AG. (4/27/17). "Press Release: Sygnis AG Reports Financial Results for Fiscal Year 2016". Madrid & Heidelberg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.